GlassScriptPhysician profile
Andrew P Stalker
NPI 1831136704
$280,411.87
in general payments reported to CMS, 2019-2025
89 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $43K · 2021: $50K · 2022: $55K · 2023: $25K · 2024: $30K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Food and Beverage: $17K · Consulting Fee: $1,085 · Education: $270 · Travel and Lodging: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,824.88 |
| Food and Beverage | $17,284.75 |
| Consulting Fee | $1,085.00 |
| Education | $270.39 |
| Travel and Lodging | $187.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $70,496.05 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $52,544.72 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Amgen INC. | $52,440.96 | 2019-2025 | Aimovig, Uplizna |
| Allergan, INC. | $26,264.39 | 2020-2022 | |
| Genzyme Corporation | $12,175.15 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $11,796.85 | 2020-2021 | |
| Acorda Therapeutics, INC | $10,227.01 | 2019-2024 | Inbrija, Ampyra |
| Biohaven Pharmaceutical Holding Company LTD. | $10,020.51 | 2022 | |
| Pfizer INC. | $7,142.36 | 2019-2025 | |
| Sk Life Science, INC. | $3,484.88 | 2020-2025 | |
| Ucb, INC. | $2,710.88 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Alexion Pharmaceuticals, INC. | $1,687.51 | 2019-2025 | Ultomiris, Soliris |
| Jazz Pharmaceuticals INC. | $1,422.53 | 2019-2025 | Xywav |
| Harmony Biosciences LLC | $1,351.27 | 2020-2025 | Wakix |
| Emd Serono, INC. | $1,318.27 | 2019-2025 | Mavenclad |
Show all 89 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Stalker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.